Mite Asthma Pediatric Immunotherapy Trial

Inclusion Criteria: * Written informed consent * Male or female of any race/ethnicity aged 5-17 years * A female subject of childbearing potential must have a negative pregnancy test and be willing to practise appropriate contraceptive methods * A clinical history of HDM allergic asthma * Use of low daily dose of ICS plus LABA or medium/high daily dose of ICS with or without LABA for the control of asthma symptoms * A clinical history of asthma exacerbations in the past two years * One or more of the following within the past 4 weeks prior to randomisation: * Daytime asthma symptoms more than twice/week * Any nocturnal awakening due to asthma * SABA rescue medication needed for treatment of asthma symptoms * Any activity limitation due to asthma * Lung function measured by FEV1 ≥ 70% of predicted value or according to local requirements * Clinical history of HDM AR within the last year prior to randomisation * An average TCRS\>0 during the baseline period * Positive specific IgE (defined as ≥class 2, ≥0.70 kU/l) against D. pteronyssinus and/or D. farinae at screening * Positive SPT to D. pteronyssinus and/or D. farinae at screening * Subject willing and able to comply with trial protocol Exclusion Criteria: * Is sensitised and regularly exposed to animal dander, molds, and/or cockroach or other perennial allergen * Has experienced a life-threatening asthma attack * Within the last month before the randomisation visit (visit 3), has had an occurrence of any clinica…